- Home
- ATHA vs AEHL Comparison
ATHA vs AEHL Comparison
Compare ATHA & AEHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATHA
- AEHL
- Stock Information
- Founded
- ATHA 2011
- AEHL 1993
- Country
- ATHA United States
- AEHL China
- Employees
- ATHA N/A
- AEHL N/A
- Industry
- ATHA Medicinal Chemicals and Botanical Products
- AEHL Building Materials
- Sector
- ATHA Health Care
- AEHL Industrials
- Exchange
- ATHA Nasdaq
- AEHL Nasdaq
- Market Cap
- ATHA 16.1M
- AEHL 17.3M
- IPO Year
- ATHA 2020
- AEHL 2007
- Fundamental
- Price
- ATHA $4.11
- AEHL $1.60
- Analyst Decision
- ATHA
- AEHL
- Analyst Count
- ATHA 0
- AEHL 0
- Target Price
- ATHA N/A
- AEHL N/A
- AVG Volume (30 Days)
- ATHA 27.3K
- AEHL 418.3K
- Earning Date
- ATHA 11-06-2025
- AEHL 12-26-2025
- Dividend Yield
- ATHA N/A
- AEHL N/A
- EPS Growth
- ATHA N/A
- AEHL N/A
- EPS
- ATHA N/A
- AEHL N/A
- Revenue
- ATHA N/A
- AEHL $98,773,000.00
- Revenue This Year
- ATHA N/A
- AEHL N/A
- Revenue Next Year
- ATHA N/A
- AEHL N/A
- P/E Ratio
- ATHA N/A
- AEHL N/A
- Revenue Growth
- ATHA N/A
- AEHL 36.99
- 52 Week Low
- ATHA $2.20
- AEHL $1.56
- 52 Week High
- ATHA $8.26
- AEHL $14.66
- Technical
- Relative Strength Index (RSI)
- ATHA 59.40
- AEHL 29.59
- Support Level
- ATHA $3.95
- AEHL $1.78
- Resistance Level
- ATHA $4.50
- AEHL $2.19
- Average True Range (ATR)
- ATHA 0.24
- AEHL 0.34
- MACD
- ATHA -0.05
- AEHL -0.12
- Stochastic Oscillator
- ATHA 55.81
- AEHL 1.05
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.
About AEHL Antelope Enterprise Holdings Limited
Antelope Enterprise Holdings Ltd operates in two reportable operating segments: 1) business management consulting, information system technology consulting services including the sales of software use rights for digital data deposit platforms and asset management systems, and online social media platform development and consulting, and 2) natural gas power generation, which was in the initial development stage. The business of the Company is engaged in the PRC and U.S.